Clinical efficacy and patient satisfaction with U-500 insulin use

被引:25
作者
Dailey, Alexandria M. [2 ]
Williams, Sarah [2 ]
Taneja, Deepa [1 ]
Tannock, Lisa R. [1 ,3 ]
机构
[1] Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA
[2] Univ Kentucky, Sch Med, Lexington, KY 40536 USA
[3] Dept Vet Affairs, Lexington, KY 40536 USA
关键词
Insulin resistance; HbA1c; Weight gain; Hypoglycemia; REGULAR INSULIN; ABSORPTION;
D O I
10.1016/j.diabres.2010.02.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: The prevalence of highly insulin-resistant diabetes is increasing and treatment requires the use of very high doses of insulin. This study was performed to analyze efficacy and patient satisfaction with use of U-500 concentrated insulin. Methods: The medical records of 40 patients using U-500 insulin for at least 3 months were reviewed. A quality of life questionnaire was administered 6 or more months after U-500 was initiated. Effects of U-500 use on HbA1c, weight, total daily insulin use, hypoglycemia, and patient satisfaction were measured. Results: Patients had uncontrolled diabetes for 3 years prior to U-500 initiation despite insulin titration. Subjects required continued insulin titration to attain glycemic control even after U-500 initiation, but HbA1c decreased by 1.5% within 3 months. Subjects gained weight with insulin titration. Hypoglycemic symptoms increased early after transition to U-500 insulin, but patients reported fewer hypoglycemic episodes on the quality of life questionnaire. Patient satisfaction with diabetes care and control was significantly improved following transition to U-500 insulin. Conclusions: Use of U-500 insulin assists with attaining glycemic control in highly insulin-resistant subjects, but at the cost of weight gain and increased insulin doses. However, patient satisfaction is improved with U-500 insulin use. Published by Elsevier Ireland Ltd.
引用
收藏
页码:259 / 264
页数:6
相关论文
共 17 条
[1]   Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients [J].
Ballani, Piya ;
Tran, Michael T. ;
Navar, Maria D. ;
Davidson, Mayer B. .
DIABETES CARE, 2006, 29 (11) :2504-2505
[2]  
BINDER C, 1969, ACTA PHARMACOL TOX, VS 27, P1
[3]  
Bulchandani Deepti G, 2007, Endocr Pract, V13, P721
[4]  
Burroughs T.E., 2004, DIABETES SPECTRUM, V17, P41, DOI [10.2337/diaspect.17.1.41, DOI 10.2337/DIASPECT.17.1.41]
[5]   Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus [J].
Crasto, W. ;
Jarvis, J. ;
Hackett, E. ;
Nayyar, V. ;
McNally, P. G. ;
Davies, M. J. ;
Lawrence, I. G. .
POSTGRADUATE MEDICAL JOURNAL, 2009, 85 (1002) :219-222
[6]  
DCCT Res Grp, 1988, DIABETES CARE, V11, P567
[7]  
Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894
[8]   FACTORS INFLUENCING THE ABSORPTION, SERUM-INSULIN CONCENTRATION, AND BLOOD-GLUCOSE RESPONSES AFTER INJECTIONS OF REGULAR INSULIN AND VARIOUS INSULIN MIXTURES [J].
GALLOWAY, JA ;
SPRADLIN, CT ;
NELSON, RL ;
WENTWORTH, SM ;
DAVIDSON, JA ;
SWARNER, JL .
DIABETES CARE, 1981, 4 (03) :366-376
[9]   U-500 insulin: why, when and how to use in clinical practice [J].
Garg, R. ;
Johnston, V. ;
McNally, P. G. ;
Davies, M. J. ;
Lawrence, I. G. .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2007, 23 (04) :265-268
[10]   10-year follow-up of intensive glucose control in type 2 diabetes [J].
Holman, Rury R. ;
Paul, Sanjoy K. ;
Bethel, M. Angelyn ;
Matthews, David R. ;
Neil, H. Andrew W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (15) :1577-1589